204 related articles for article (PubMed ID: 28274968)
1. Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study.
Arroyo R; Sempere AP; Ruiz-Beato E; Prefasi D; Carreño A; Roset M; Maurino J
BMJ Open; 2017 Mar; 7(3):e014433. PubMed ID: 28274968
[TBL] [Abstract][Full Text] [Related]
2. Factors Associated with Patient Preferences for Disease-Modifying Therapies in Multiple Sclerosis.
Hincapie AL; Penm J; Burns CF
J Manag Care Spec Pharm; 2017 Aug; 23(8):822-830. PubMed ID: 28737987
[TBL] [Abstract][Full Text] [Related]
3. Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.
Wilson L; Loucks A; Bui C; Gipson G; Zhong L; Schwartzburg A; Crabtree E; Goodin D; Waubant E; McCulloch C
J Neurol Sci; 2014 Sep; 344(1-2):80-7. PubMed ID: 25037284
[TBL] [Abstract][Full Text] [Related]
4. Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options.
Jonker MF; Donkers B; Goossens LMA; Hoefman RJ; Jabbarian LJ; de Bekker-Grob EW; Versteegh MM; Harty G; Wong SL
Med Decis Making; 2020 Feb; 40(2):198-211. PubMed ID: 32065023
[No Abstract] [Full Text] [Related]
5. Preferences for Disease-Modifying Therapies in Argentina: Cross-Sectional Conjoint Analysis of Patients and Neurologists.
Rojas JI; Patrucco L; Alonso R; Lopez PA; Deri N; Pettinicchi JP; Cristiano E; Carnero Contentti E
Value Health Reg Issues; 2022 Sep; 31():93-100. PubMed ID: 35640464
[TBL] [Abstract][Full Text] [Related]
6. Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices.
Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
Patient; 2023 Sep; 16(5):457-471. PubMed ID: 37072663
[TBL] [Abstract][Full Text] [Related]
7. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Burt RK; Balabanov R; Burman J; Sharrack B; Snowden JA; Oliveira MC; Fagius J; Rose J; Nelson F; Barreira AA; Carlson K; Han X; Moraes D; Morgan A; Quigley K; Yaung K; Buckley R; Alldredge C; Clendenan A; Calvario MA; Henry J; Jovanovic B; Helenowski IB
JAMA; 2019 Jan; 321(2):165-174. PubMed ID: 30644983
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.
Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
Patient; 2020 Oct; 13(5):583-597. PubMed ID: 32588337
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
[TBL] [Abstract][Full Text] [Related]
10. Teriflunomide for multiple sclerosis.
He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
[TBL] [Abstract][Full Text] [Related]
11. Using a multidimensional unfolding approach to assess multiple sclerosis patient preferences for disease-modifying therapy: a pilot study.
Sempere AP; Vera-Lopez V; Gimenez-Martinez J; Ruiz-Beato E; Cuervo J; Maurino J
Patient Prefer Adherence; 2017; 11():995-999. PubMed ID: 28615928
[TBL] [Abstract][Full Text] [Related]
12. Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis.
Wilson LS; Loucks A; Gipson G; Zhong L; Bui C; Miller E; Owen M; Pelletier D; Goodin D; Waubant E; McCulloch CE
Int J MS Care; 2015; 17(2):74-82. PubMed ID: 25892977
[TBL] [Abstract][Full Text] [Related]
13. Patients' preferences and willingness-to-pay for disease-modifying therapies.
Frost N; Freeman J; Brixner D; Mort J; Clem J; Ngorsuraches S
Mult Scler Relat Disord; 2019 Oct; 35():55-60. PubMed ID: 31323483
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
[TBL] [Abstract][Full Text] [Related]
15. Reasons patients give to use or not to use immunomodulating agents for multiple sclerosis.
Visser LH; van der Zande A
Eur J Neurol; 2011 Nov; 18(11):1343-9. PubMed ID: 21496180
[TBL] [Abstract][Full Text] [Related]
16. Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment.
Garcia-Dominguez JM; Muñoz D; Comellas M; Gonzalbo I; Lizán L; Polanco Sánchez C
Patient Prefer Adherence; 2016; 10():1945-1956. PubMed ID: 27713622
[TBL] [Abstract][Full Text] [Related]
17. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.
Bsteh G; Feige J; Ehling R; Auer M; Hegen H; Di Pauli F; Deisenhammer F; Reindl M; Berger T
Mult Scler; 2017 Aug; 23(9):1241-1248. PubMed ID: 27765877
[TBL] [Abstract][Full Text] [Related]
20. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
